Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk A/S (NVO) is having one of its best days in more than two months, with shares popping 2.58% -- their highest percentage gain since May 2 -- shortly after the market opened Thursday. NOV added $1.18 to $46.83 after Novo Nordisk released positive late-stage test results for two drugs designed to treat diabetes.

The drugs, PIONEER 4 and PIONEER 7, both met analyst expectations for reducing the amount of a protein that affects people's blood-sugar levels, but "demonstrated statistically significant and superior reductions in body weight" when compared to competitors, Nova Nordisk said in a statement.

Jefferies analysts estimate the drugs could enjoy $4.5 billion in peak sales if the substances win U.S. Food and Drug Administration approval, according to Bloomberg data.

More from Stocks

IBM, Microsoft, Papa John's and UnitedHealth - 5 Things You Must Know

IBM, Microsoft, Papa John's and UnitedHealth - 5 Things You Must Know

UnitedHealth Could Strike Deal for Tenet's Conifer Subsidiary: Reports

UnitedHealth Could Strike Deal for Tenet's Conifer Subsidiary: Reports

One Chart Will Make You Even More Pumped Up to Buy Tech Stocks

One Chart Will Make You Even More Pumped Up to Buy Tech Stocks

Google Shares Shrug Off $5 Billion EU Fine Against Alphabet

Google Shares Shrug Off $5 Billion EU Fine Against Alphabet

Jim Cramer's Biggest Moments From Delivering Alpha

Jim Cramer's Biggest Moments From Delivering Alpha